🚨🚨🚨
RASOLUTE-302 Ph3 is POSITIVE
"Daraxonrasib demonstrated a median OS of 13.2 months versus 6.7 months for chemotherapy, with a hazard ratio of 0.40 (p < 0.0001)".... WOW!
AMAZING news for patients with #PancreaticCancer
The RAS Revolution is ON!!
https://t.co/I59NNWRB1O
New preprint from @dkfchang@UofGCancerSci:
Morpho-spatial profiling of cancer-associated fibroblasts reveals architectural subtypes of #PancreaticCancer
https://t.co/B7pyzngaxO
Morphology 🤝 Biology
🚨Registration is now open for the Cancer Research UK Pancreatic Cancer Conference 2026!🚨
Join me and my conference co-chairs @Aiims1742@SaurLab for the inaugural meeting in London, UK, from 7-9 July 2026, hosted by @CR_UK. 💜
Find out more: https://t.co/Uuwm1mNWsl
Dr. @dkfchang and colleagues provide in vitro evidence of a novel therapeutic strategy to overcome acquired resistance to PARP inhibitor and platinum in #PDAC, using sequential exposure to ceralasertib and olaparib.
💡 Learn more: https://t.co/i9s5msnJvF
I’m delighted to have been elected @RoyalSocEd President from April 2025. I’m grateful to the Fellows of the RSE for their support. Looking forward to working with you in the coming years, and further extending our collaborations in Scotland, the U.K. and at international level.
😀I was wondering when this would come out - this is so exciting‼️
🤔I know some may say this is a rare population, and it is
👉🏼BUT a ~40% response in >=2nd line #PancreaticCancer is still very, very clinically meaningful👏🏼
🙏🏼AND - we HAVE TO remember to test for this🧬🧬🧬🧬🧬🧬
There is 'snow' place like the University of Glasgow!
Campus has been transformed into a magical winter wonderland ❄️
Stay safe & warm out there, folks!
#Snow#Glasgow#TeamUofG